The latest announcement is out from Race Oncology Ltd. ( (AU:RAC) ).
Race Oncology Ltd has announced the approval of a Phase 1 clinical trial for its reformulated bisantrene, RC220, by the Bellberry Human Research Ethics Committee. This trial will evaluate the safety and efficacy of RC220 in combination with doxorubicin, focusing on cardiac and clinical biomarkers. The company is hosting an online investor briefing to discuss the trial details, aiming to strengthen its position in the oncology market by addressing high unmet needs and exploring partnerships to expand access to its treatments.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is a clinical-stage biopharmaceutical company focused on cancer care. Its lead product, bisantrene, is a chemotherapeutic agent with a unique clinical history, offering therapeutic benefits with less cardiotoxicity compared to traditional anthracyclines. The company is advancing a reformulated version, RC220, to address unmet needs in oncology, particularly in combination therapies for solid tumors and as a treatment for acute myeloid leukemia. Race is also investigating the effects of bisantrene on the m6A RNA pathway, which is implicated in various cancers.
YTD Price Performance: -25.93%
Average Trading Volume: 80,528
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$183.3M
For an in-depth examination of RAC stock, go to TipRanks’ Stock Analysis page.